Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing Chinas first immunotherapy bi-specific antibody approved for...
Source: prnewswire.com